---
schema_version: "secwatch.filing_event.v1"
accession: "0001048477-25-000088"
form_type: "8-K"
ticker: "BMRN"
cik: "0001048477"
company_name: "BIOMARIN PHARMACEUTICAL INC"
filed_at: "2025-08-04T23:59:59+00:00"
generated_at: "2026-05-17T21:19:47.377928+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# BioMarin Q2 revenue $825M (+16% Y/Y); GAAP EPS $1.23 (+124%); raises full-year guidance

## Summary
- Total revenue $825M, +16% Y/Y; GAAP net income $241M (vs $107M) and diluted EPS $1.23 (+124%).
- Non-GAAP diluted EPS $1.44 (+50%); N-GAAP operating margin 39.9% (up 8.7pp Y/Y).
- VOXZOGO revenue $221M (+20%) and Enzyme Therapies $555M (+15%); KUVAN down 7% to $27M.
- Raised FY2025 guidance for total revenues, non-GAAP operating margin, and non-GAAP diluted EPS.
- Completed Inozyme acquisition (July); BMN 333 (achondroplasia) Phase 2/3 to start 1H'26; BMN 390 discontinued.

## SEC filing metadata
- accession: 0001048477-25-000088
- form_type: 8-K
- ticker: BMRN
- cik: 0001048477
- company_name: BIOMARIN PHARMACEUTICAL INC
- filed_at: 2025-08-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1048477/000104847725000088/0001048477-25-000088-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1048477/000104847725000088/bmrn-20250804.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001048477-25-000088
- JSON: https://secwatch.observer/filing/0001048477-25-000088.json
- Plain text: https://secwatch.observer/filing/0001048477-25-000088.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.